Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
|Number of Rows||16|
|Number of Columns||24|
|Well volume||28 µL|
|Recommended working volume||10 µL- 20 µL|
|Well diameter (mm)||3.3|
|Well depth (mm)||5.3|
|A1 to top offset (mm)||8.99|
|A1 to side offset (mm)||12.13|
|Well-to-well spacing (mm)||4.5|
|Detection Method||Luminescence, Alpha|
|Product Brand Name||AlphaPlate|
|Unit Size||Case of 50|
|Wells Number||384 well plate|
A variety of chemotherapeutic drugs with different modes of action have been developed and tested as potential therapies for colorectal cancer. Characterizing the effects of potential drugs with different modes of action is a key part of the process.
In this application note you will learn:
Technical advancements in antibody engineering has brought about greater interest in more novel antibody therapeutic design and the emergence of new classes of antibody therapeutics called bispecific antibodies (bsAbs). The principle behind bispecific antibody design is to create an antibody / antibody fragment to two or more binding sites to help with the treatment of complex diseases.
As more bsAbs are produced as therapeutics, fast and accurate methods for functionally evaluating and characterizing the stability of these antibodies are necessary during both discovery and development stages, as well as during formulation and quality analysis.
In this application note, we demonstrate how AlphaLISA® assay technology with the EnVision® multimode plate reader can be used for bispecific antibody detection, through an example application to characterize the binding and specificity of a mouse bispecific antibody targeting mouse TIGIT and mouse PD-L1.
You will find out: